Reported results
- Third-quarter 2026 royalty revenue was $70.3 million, compared with $46.6 million for the prior-year period.
- Total revenues and income for the third quarter of 2026 were $78.7 million, compared with $115.5 million for the prior-year period.
- GAAP net loss was $28.5 million, or $1.43 per share, for the third quarter of 2026.
- Adjusted net income was $57.5 million, or $2.67 per diluted share, for the third quarter of 2026.
- As of September 30, 2026, Ligand had cash, cash equivalents, and short-term investments of $447.4 million.
Guidance
- Royalty revenue of $225 million to $250 million
- Captisol sales of $35 million to $40 million
- Contract revenue of $10 million to $20 million
- Total revenue of $270 million to $310 million
- Adjusted earnings per diluted share of approximately $9.50 to $9.75
Notes
Prior-year results included $53.1 million of income related to the Pelthos divestiture; results for the third quarter of 2026 included $39.5 million of pre-tax losses related to fair value changes of investments.
Price and volatility reaction
The stock moved -0.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 318.78 | 2026-10-28 |
| Close after release | 317.33 | 2026-10-29 |
| Realised move | -0.5% | close to close |
| 30d ATM IV change | -4.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
